The marker, called the N-CALLY index, is elegantly simple in its construction. It is calculated by multiplying the neutrophil-to-lymphocyte ratio, a standard gauge of systemic inflammation derived from a complete blood count, by the C-reactive protein-to-albumin ratio, which pairs an acute-phase inflammatory protein with a measure of nutritional reserve. Both components have individually been linked to cancer outcomes in previous research, but the Osaka team, led by Iguru Omori and Hiroaki Kasashima, reasoned that multiplying them together might capture something that neither could alone: the combined burden of inflammation and nutritional decline that often accompanies advancing disease.

The study, published in BMC Cancer, analyzed 76 patients who developed pulmonary metastasis after undergoing curative resection of their primary colorectal cancer between January 2008 and December 2022. One outlier case was excluded from the initial cohort of 77 consecutive patients. The researchers measured the N-CALLY index and a battery of competing inflammatory, nutritional, and skeletal muscle indices at the exact moment each patient’s lung metastasis was diagnosed, then tracked overall survival using the statistical tools that underpin modern prognostic research: receiver operating characteristic analysis to find the best cut-off, Kaplan-Meier curves to visualize survival differences, and Cox proportional hazards regression to test whether the index held up after accounting for other clinical factors.

The results were striking for a marker that costs nothing beyond tests already performed in routine care. Among all the systemic inflammatory and nutritional indices examined, the N-CALLY index showed the highest area under the receiver operating characteristic curve, at 0.628, with a cohort-derived cut-off value of 0.03. Patients whose index was at or above that threshold faced significantly worse overall survival. In univariate analysis, an elevated index carried a hazard ratio of 3.524, with a 95 percent confidence interval of 1.536 to 8.084 and a p-value of 0.003. Crucially, the association survived multivariable adjustment, with an adjusted hazard ratio of 3.014 and a confidence interval of 1.285 to 7.068, meaning the index predicted survival independently of established clinicopathological factors.

Perhaps the most clinically relevant finding came when the researchers tested whether adding the N-CALLY index to a conventional prognostic model actually improved that model’s performance. Using time-dependent receiver operating characteristic analysis, they found that the model including the index achieved higher area under the curve values for predicting one-, three-, and five-year overall survival than the model without it: 0.730 versus 0.619 at one year, 0.771 versus 0.705 at three years, and 0.758 versus 0.721 at five years. The apparent concordance index, a standard measure of a model’s ability to rank patients correctly by risk, rose from 0.662 to 0.708, and after bootstrap correction for optimism, from 0.645 to 0.686. In plain terms, the blood-based formula made the risk predictions measurably sharper across every time horizon tested.

The biology behind the index is grounded in a growing body of research on the systemic inflammatory response in cancer. Neutrophils, the abundant white blood cells that mount the first line of defense against infection, can be recruited by tumors and can actively promote invasion, angiogenesis, and metastatic seeding. Lymphocytes, by contrast, are the immune system’s primary anti-tumor warriors, and their depletion signals an immunosuppressed, tumor-tolerant state. A high neutrophil-to-lymphocyte ratio therefore reflects an immune environment tilted in the cancer’s favor. C-reactive protein, produced by the liver under inflammatory stimulation, rises when tumors drive chronic systemic inflammation, while albumin falls as inflammation suppresses appetite and accelerates protein breakdown. By multiplying the two ratios, the N-CALLY index effectively asks whether a patient is simultaneously inflamed and nutritionally depleted, a combination that previous work has repeatedly associated with poor outcomes across many cancer types.

Why does this matter specifically for lung metastases from colorectal cancer? Pulmonary metastasectomy, the surgical removal of lung lesions, remains a mainstay of treatment for selected patients, but deciding who truly benefits from an operation is one of the most debated questions in gastrointestinal oncology. Current selection relies heavily on the number, size, and resectability of lesions, the disease-free interval, and the status of lymph nodes, yet these criteria leave considerable uncertainty. A blood test that adds independent prognostic information could, in principle, help clinicians and patients weigh the risks and benefits of surgery versus systemic therapy, or help identify patients whose disease biology warrants closer surveillance or earlier escalation of treatment.

The authors are careful, and appropriately so, about the limits of their work. This was a retrospective, single-center study of a modest 76 patients, and the cut-off of 0.03 was derived from the same cohort in which it was tested, a practice that tends to inflate apparent performance. The area under the curve of 0.628, while the best among the indices compared, indicates only moderate discriminatory power on its own. The researchers explicitly state that the N-CALLY index should serve as an adjunctive marker to complement established clinicopathological factors, not as a stand-alone criterion for deciding who undergoes pulmonary metastasectomy or any other treatment. They call for validation in independent external cohorts before any clinical application, a caution that reflects the well-documented tendency of prognostic markers to perform less impressively when tested outside their birthplace.

Still, the appeal of the approach is hard to overstate. Unlike genomic assays or advanced imaging, the N-CALLY index requires only a complete blood count, a C-reactive protein measurement, and an albumin level, tests that are already ordered for virtually every cancer patient at every major hospital. It costs pennies, can be computed on a napkin, and delivers a single number that quantifies the intersection of two of the most powerful forces shaping cancer outcomes: the body’s inflammatory state and its nutritional reserve. If larger, multi-center studies confirm the Osaka findings, this humble formula could find its way into the risk stratification schemes that guide care for the growing population of patients living with colorectal cancer that has reached the lungs, offering a faster, cheaper complement to the clinical judgment on which oncologists have long had to rely.

Subject of Research: Prognostic value of a composite inflammatory–nutritional blood index for risk stratification in colorectal cancer patients with pulmonary metastasis

Article Title: Risk stratification in patients with pulmonary metastasis from colorectal cancer: prognostic utility of a composite inflammatory–nutritional index (N-CALLY index) — a retrospective cohort study

Article References: Omori, I., Kasashima, H., Fukuoka, T., Wang, Z., Naito, N., Tanaka, A., Yonemitsu, K., Fukui, Y., Seki, Y., Kuroda, K., Miki, Y., Yoshii, M., Tamura, T., Shibutani, M., Toyokawa, T., & Maeda, K. (2026). Risk stratification in patients with pulmonary metastasis from colorectal cancer: prognostic utility of a composite inflammatory–nutritional index (N-CALLY index) — a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17055-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17055-2

Keywords: colorectal cancer, pulmonary metastasis, N-CALLY index, prognostic marker, systemic inflammation, neutrophil-to-lymphocyte ratio, C-reactive protein, albumin, overall survival, risk stratification, pulmonary metastasectomy, retrospective cohort study

Differentiated high-grade thyroid carcinoma entered the official medical lexicon with the 2022 revision of the World Health Organization classification of thyroid tumors. The category was created to capture a troubling intermediate entity: tumors that retain the recognizable microscopic architecture of differentiated thyroid cancer, the well-behaved papillary and follicular patterns that typically respond well to surgery and radioactive iodine, yet display unmistakable signs of aggressive biological behavior. Under the WHO definition, a differentiated high-grade tumor must show tumor necrosis, meaning patches of dead malignant tissue where the cancer has outgrown its blood supply, or an elevated mitotic count of at least five mitoses per two square millimeters, indicating rapid cellular division. Either finding, layered on top of differentiated morphology, signals a tumor that may behave far worse than its appearance alone would suggest.

The patient in this report arrived with classic compressive symptoms. Dyspnea, or difficulty breathing, and dysphagia, difficulty swallowing, are alarming signs when a neck mass is the culprit, because the thyroid gland sits directly in front of the trachea and esophagus. A six-year history of slow enlargement raises difficult questions about why earlier intervention did not occur, and the case underscores a persistent global problem: slowly growing thyroid masses can be tolerated or overlooked for years until they become bulky, symptomatic, and significantly harder to remove. By the time this patient reached the operating theater, the mass qualified as a giant clinical neck mass, a descriptive term for tumors large enough to distort cervical anatomy and complicate standard surgical technique.

In July 2024, the surgical team performed a total thyroidectomy, the complete removal of the thyroid gland, together with a bilateral central lymph node dissection clearing the compartment behind and beside the thyroid, and a right lateral neck dissection covering lymph node levels II through V. The extent of the operation reflects how thoroughly the disease had spread through the neck’s drainage basins. Pathological examination of the removed tissue confirmed bilateral differentiated high-grade thyroid carcinoma involving both thyroid lobes, with visible tumor necrosis, more than five mitoses per two square millimeters, and multifocal vascular invasion, meaning cancer cells had invaded blood vessels at multiple sites, a well-established risk factor for distant metastasis. Importantly, the surgical margins were negative, and there was no extrathyroidal extension, meaning the tumor had not grown through the thyroid capsule into surrounding neck structures. Lymph node analysis revealed metastatic disease in seven of thirteen central nodes and three of six right lateral nodes, resulting in a pathological stage of pT3a pN1b.

What happened next illustrates both the promise and the limitations of radioactive iodine therapy, the hallmark systemic treatment for differentiated thyroid cancer. Radioactive iodine exploits a unique property of thyroid cells: their ability to actively transport iodine through the sodium-iodide symporter. When differentiated thyroid cancer cells retain this transporter, they can be selectively irradiated from within by ingested radioactive iodine, a treatment with comparatively few side effects because non-thyroid tissues absorb little of the isotope. A diagnostic scan performed in September 2024 demonstrated that the patient’s mediastinal and pulmonary metastases were iodine-avid, meaning the lung and chest deposits visibly concentrated the radioactive tracer. This finding classified her disease as distant metastatic disease, designated cM1, but also offered genuine hope, because iodine-avid metastases are typically considered candidates for effective radioiodine ablation.

Two courses of radioactive iodine treatment were documented. Initial follow-up appeared encouraging: imaging in March 2025 showed improvement in the pulmonary metastases, and the treatment team had reason to believe the iodine-avid disease was responding. However, the trajectory shifted over the following months. By June 2025, the patient’s serum thyroglobulin, a protein produced almost exclusively by thyroid tissue and widely used as a tumor marker for differentiated thyroid cancer after thyroidectomy, had climbed to 656.85 nanograms per milliliter, a level far above the near-undetectable values expected in disease-free patients. In September 2025, pulmonary computed tomography revealed mixed changes, with some lesions improving while others progressed or evolved, and thyroglobulin remained above 500 nanograms per milliliter, confirming that substantial metabolically active thyroid cancer tissue persisted despite therapy.

The reporting authors are appropriately careful about what these findings do and do not prove. Because the exact administered radioactive iodine activities were missing from the record and the imaging and biochemical tests were not fully synchronized in time, the case cannot be definitively classified as radioactive iodine-refractory disease, the formal designation for tumors that either never take up iodine or progress after appropriate radioiodine treatment. This distinction matters enormously for clinical decision-making, since refractory disease opens the door to kinase inhibitors and other targeted therapies, while iodine-avid disease generally argues for repeated radioiodine courses. The authors also note a subtle but important point of precision: the frequently cited 13-centimeter figure describes the clinical mass measured in the neck, not the diameter of a single pathological tumor specimen, a reminder that careful measurement conventions matter when comparing cases across the literature.

Longitudinal evidence on giant thyroid tumors treated with radioactive iodine remains limited, which is precisely why this case report includes a focused review of the existing literature. Most large series of differentiated high-grade thyroid carcinoma emphasize its intermediate position on the aggressiveness spectrum: distinctly worse than conventional papillary and follicular carcinoma, yet generally less explosive than poorly differentiated carcinoma or anaplastic thyroid carcinoma, the almost uniformly fatal undifferentiated form. Differentiated high-grade tumors carry elevated rates of recurrence and distant metastasis, and the presence of necrosis and high mitotic activity has been linked to poorer disease-specific survival in multiple studies. This case adds a valuable data point by documenting the full arc from giant untreated primary tumor through surgery, radioiodine response, and eventual biochemical and radiographic progression over roughly two years of follow-up.

At last contact on August 26, 2026, the patient was alive and reported generalized pain and low-back pain, symptoms that raise the specter of skeletal metastasis, a common distant site for aggressive thyroid cancer, although no imaging confirmation of new metastases was available at the time of the report. Her course delivers several sobering lessons for clinicians and patients alike. First, differentiated appearance on the microscope does not guarantee indolent behavior once necrosis and brisk mitotic activity are present, so the 2022 WHO criteria deserve active application in every thyroid pathology report. Second, early post-treatment improvement after radioactive iodine does not establish durable control, and biochemical surveillance with thyroglobulin remains indispensable for catching treatment failure. Third, slowly enlarging neck masses deserve evaluation long before they become symptomatic, because a six-year delay transformed a potentially straightforward thyroidectomy into a major oncological operation with distant disease already established. As differentiated high-grade thyroid carcinoma becomes more widely recognized, cases like this one will help define its natural history and sharpen the decisions that follow.

Subject of Research: Differentiated high-grade thyroid carcinoma presenting as a giant neck mass with iodine-avid pulmonary metastases

Article Title: Diffuse bilateral differentiated high-grade thyroid carcinoma presenting as a giant clinical neck mass with iodine-avid pulmonary metastases: a case report and focused literature review

Article References: Gao, S., Xu, X., & Wei, W. (2026). Diffuse bilateral differentiated high-grade thyroid carcinoma presenting as a giant clinical neck mass with iodine-avid pulmonary metastases: a case report and focused literature review. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02559-6

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02559-6

Keywords: differentiated high-grade thyroid carcinoma, thyroid cancer, giant neck mass, pulmonary metastasis, radioactive iodine, total thyroidectomy, thyroglobulin, WHO classification 2022, case report, lymph node metastasis, endocrine cancer, BMC Endocrine Disorders